We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Technique to Explain Patterns of Gene Regulation

By Biotechdaily staff writers
Posted on 28 Dec 2004
Scientists have developed a technique for identifying control elements that drive the expression of genes in brain cells, which could lead to a better understanding of the pathways behind genetic aberrations that cause diabetes, Parkinson's disease, heart disease, and cancer.

The technique resulted from an effort to characterize a family of genes regulated by the cAMP response binding protein (CREB). More...
This molecule is one of a group of transcription factors that interact with regulatory elements in DNA responsible for increasing or decreasing the level of gene expression in cells.

The technique involves linking DNA from a cell with the transcription factor protein, then isolating the complex through immunoprecipitation. Strips of 21-nucleotide-long DNA are then released from the immunoprecipitated DNA to create genomic signature tags, which are then identified in the international genome database. The method has uncovered about 6,300 regulatory regions that mapped to distinct sites on the genome.

The technique was developed by scientists at the Vollum Institute of Oregon Health & Science University (OHSU, Portland, OR, USA), in collaboration with other scientists at Brookhaven U.S. National Laboratory (Upton, NY, USA) and the State University of New York, Stony Brook (NY, USA). Their multidisciplinary study appears in the December 29, 2004 issue of Cell.

Richard Goodman, M.D., Ph.D., professor of cell and developmental biology at OHSU's School of Medicine and director of the Vollum Institute, calls the new process "the most comprehensive analysis to date in a metazoan system--that is, a multicellular system--of where transcription factors bind to their genomic targets.”

"In the past,” he observed, "it's only been possible to look at a very small part of the genome, but now we can look at the whole thing. It's a big step forward.” Scientists are already utilizing the technique in new research projects.


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
POC Immunoassay Analyzer
Procise DX
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.